The non-covalent interactions that stabilize protein tertiary and quaternary structures include: Select all that apply
Hydrogen bonds
Covalent bonds
Hydrophobic interactions
Ionic bonds
Disulfide bonds
Correct Answer : A,C,D
Protein tertiary and quaternary structures are maintained through a variety of intramolecular forces that ensure proper folding and stability. Tertiary structure refers to the three-dimensional arrangement of a single polypeptide, while quaternary structure involves the assembly of multiple subunits. While covalent bonds like disulfide bridges provide strong linkages, non-covalent interactions are the primary drivers of protein dynamics and folding energetics.
Rationale:
A. Hydrogen bonds occur when a hydrogen atom covalently bonded to an electronegative atom is attracted to another electronegative atom. These bonds are essential for stabilizing both secondary structures and the intricate folding patterns of tertiary and quaternary assemblies. They provide specificity and stability to the internal architecture of the protein.
B. Covalent bonds involve the sharing of electron pairs between atoms, creating very strong chemical links. Because the question explicitly asks for non-covalent interactions, covalent bonds are excluded by definition. Examples like peptide bonds and disulfide linkages are covalent and require high energy to break compared to weaker attractions.
C. Hydrophobic interactions are the primary driving force in protein folding, sequestering non-polar side chains away from the aqueous environment. This entropy-driven process results in a hydrophobic core that stabilizes the globular shape of proteins. It is a fundamental non-covalent force that maintains the protein's native three-dimensional conformation.
D. Ionic bonds, also known as salt bridges, form between positively and negatively charged R-groups of amino acids. These electrostatic attractions help anchor different parts of the polypeptide chain or different subunits together in quaternary complexes. They are sensitive to pH changes but are key non-covalent stabilizing factors.
E. Disulfide bonds are strong linkages formed between the sulfhydryl groups of two cysteine residues. Although they are vital for the structural integrity of many extracellular proteins, they are covalent bonds. Since the question specifies non-covalent interactions, this choice is scientifically incorrect in this specific context.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is ["48"]
Explanation
Step 1 is to convert volume and time
2 L × 1000 = 2000 mL
14 hr × 60 = 840 min
Step 2 is to calculate drops per minute
(2000 × 20) ÷ 840
2000 × 20 = 40000
40000 ÷ 840 = 47.619
Result at this step = 47.619
Step 3 is to round to the nearest whole number
47.619 ≈ 48
Answer: 48
Correct Answer is D
Explanation
Montelukast sodium is a selective leukotriene receptor antagonist (LTRA) that blocks the action of cysteinyl leukotrienes (CysLT1). These inflammatory mediators are potent bronchoconstrictors and contributors to airway edema and mucus secretion. It is used as a maintenance therapy to prevent chronic respiratory symptoms. It is frequently prescribed for patients who have concomitant asthma and allergies.
Rationale:
A. Allergic rhinitis is an FDA-approved indication for montelukast. It is effective for both seasonal and perennial allergic rhinitis in adults and pediatric patients. It helps relieve symptoms such as nasal congestion, sneezing, and rhinorrhea by blocking leukotriene-mediated inflammation in the nasal mucosa and upper respiratory tract.
B. Prevention of exercise-induced bronchoconstriction (EIB) is a specifically approved indication for montelukast. It is taken at least 2 hours before exercise to provide protection for up to 24 hours. This makes it an alternative for patients who do not achieve adequate control with short-acting beta agonists alone.
C. Asthma is the primary FDA-approved indication for montelukast sodium. It is used for the long-term prophylaxis and chronic treatment of asthma in patients as young as 12 months. It helps reduce the frequency of asthma attacks but is never used to treat an acute exacerbation or status asthmaticus.
D. COPD (Chronic Obstructive Pulmonary Disease) is not an FDA-approved indication for montelukast. While leukotrienes are present in COPD, clinical trials have not consistently shown that LTRAs provide significant benefit for airflow obstruction in this population. Maintenance of COPD typically relies on long-acting bronchodilators and inhaled corticosteroids instead.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
